Thank product for Oncternal, and needs. pipeline At everyone. with you, candidates cancers target unmet are and clinical robust focused pre medical Rich, and advancing -clinical that good patients a product afternoon, with we
ZILO-XXX the including XXXX, our key unprecedented Zilovertamab high of initiation significant an mantle macro initiated achievement our malignancies global is We Registrational our Orphan in made pipeline X, zilovertamab that we Phase of which first with inhibits in quarter navigated During Study for on we receptor. patients cell today's in is a environment, of quarter third with by you function market the sharpened in affinity cancer ROR-X the or focus be the continuing binding kinase, got. humanized first-in-class stock important further XXXX. to second is monoclonal Receptor antibody catalyst quarter, as potentially which the III toward planned of receptor the biologically tyrosine investigational, on lymphoma, like obviously in prostate to immunologic progress epitope challenging
to Study countries as We situation sites caused the robust ensure for we by III to Ukraine. the evaluate additional disruptions study Phase mitigate continue in enrollment in
data a ZILO-XXX X, As the is study providing in of to plan, year's the consensus Meeting Oncology the Society of at that ibrutinib, with major combination American and Phase in ceryl in We June study FDA by a details supported clinical on data zilovertamab trial this we on X update study. XXXX. the reminder, of design look reached encouraging forward which our Chicago with from ongoing Clinical
and manufacturing CAR-T Dana-Farber first-in-human mid-XXXX. Our studies. patients to an agreement CD-XX, we failed collaborative upcoming on relapsed for initial is continues IND have who with plan autologous ROR-X, CAR-T enroll also pro in for Cancer our cell filing to study, Phase book program those CGMP XXX targeting in process a our or advance Institute In CAR-T X including activities and clinical track malignancies, with use development therapy. the manufacturing established hematologic refractory cell conduct We to
the facility off-the-shelf to to be program. have cell technology in some at our best with and next ROR-X selected therapy generation cell other data of the proved cell world, manufacturing Our encouraging Institute for RORX the with Karolinska the fit the Cellularity with our we for Dana-Farber a partners collaborations Research processing CAR-T -based perfect continue program. and generate
receptor for our enabling prostate alternative or IND of towards program, candidate and - advanced DAARI novel cancer. highly lead to the differentiated dual androgen advance ONCT-XXX, be patients continues a inhibitor with ONCT-XXX, Next, treatment studies. action may
needs models, with believe relevant clinically significant those variants, with we splice inhibiting for prostate of and it its as have with prostate the data anti-tumor such its or VX, cancer function amplification, domains activity ONCT-XXX receptor -clinical all binding Pre enzalutamide inducing ligand the resistance, androgen interacts medical and that receptor, tumors terminal including As of AR cancer. both in degradation. end shown which exerts the patients represent - expressing unmet AR androgen
towards of hematologic enrollment X, we capital sarcoma. transformation-specific deploying the the asset, along to related inhibitor and while study, evaluating will or with catalysts, refractory resource to our X with zilovertamab. those ONCT-XXX Ewing relapsed in ONCT-XXX on deep prioritization further or of prostate Phase the ETS EXX Finally, our allow This us meaningful announced in malignancies lead especially development reallocation patients discontinuation our focus cancer of
CFO, Let Vincent. to turn Oncternal call back me now Rich the
